GeneDx Holding Overview
- Year Founded
-
2000
- Status
-
Public
- Employees
-
1,300
- Stock Symbol
-
WGS
- Investments
-
3
- Share Price
-
$45.34
- (As of Friday Closing)
GeneDx Holding General Information
Description
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.
Contact Information
Website
www.genedx.comCorporate Office
- 333 Ludlow Street
- North Tower, 6th floor
- Stamford, CT 06902
- United States
Corporate Office
- 333 Ludlow Street
- North Tower, 6th floor
- Stamford, CT 06902
- United States
GeneDx Holding Timeline
GeneDx Holding Stock Performance
As of 20-Nov-2026, GeneDx Holding’s stock price is $45.34. Its current market cap is $1.36B with 30M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $45.34 | $49.19 | $32.21 - $170.87 | $1.36B | 30M | 865K | -$3.76 |
GeneDx Holding Financials Summary
As of 30-Sep-2026, GeneDx Holding has a trailing 12-month revenue of $461M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 2,191,024 | 3,717,413 | 2,111,093 | 30,701 |
| Revenue | 460,784 | 427,539 | 305,450 | 202,566 |
| EBITDA | (79,708) | 6,626 | (27,644) | (144,073) |
| Net Income | (111,049) | (21,021) | (52,286) | (175,767) |
| Total Assets | 526,484 | 523,710 | 419,380 | 418,756 |
| Total Debt | 215,384 | 113,168 | 117,379 | 119,273 |
GeneDx Holding Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
GeneDx Holding Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
GeneDx Holding Comparisons
Industry
Financing
Details
GeneDx Holding Competitors (19)
One of GeneDx Holding’s 19 competitors is Invitae, a Formerly VC-backed company based in San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Invitae | Formerly VC-backed | San Francisco, CA | ||||
| Natera | Formerly VC-backed | Austin, TX | ||||
| MedGenome Labs | Venture Capital-Backed | Bangalore, India | ||||
| Adaptive Biotechnologies | Formerly VC-backed | Seattle, WA | ||||
| Admera Health | Venture Capital-Backed | South Plainfield, NJ |
GeneDx Holding Patents
GeneDx Holding Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260234715-A1 | Methods and systems for modeling inference of mutation impact | Pending | 11-Feb-2025 | ||
| WO-2026173905-A1 | Methods and systems for modeling inference of mutation impact | Pending | 11-Feb-2025 | ||
| US-20260098301-A1 | Methods and systems for processing genetic variations and phenotypes | Pending | 08-Oct-2024 | ||
| WO-2026080446-A1 | Methods and systems for processing genetic variations and phenotypes | Pending | 08-Oct-2024 | ||
| US-20260057139-A1 | Methods and systems for phenotypic fit analysis | Pending | 23-Aug-2024 | G16B30/00 |
GeneDx Holding Signals
GeneDx Holding Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
GeneDx Holding Investments & Acquisitions (3)
GeneDx Holding’s most recent deal was a Merger/Acquisition with Fabric Genomics for . The deal was made on 05-May-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Fabric Genomics | 05-May-2025 | Merger/Acquisition | Enterprise Systems (Healthcare) | ||
| CM Life Sciences | 22-Jul-2021 | Merger/Acquisition | Special Purpose Acquisition Company (SPAC) | ||
| Detect Genomix | 12-Aug-2020 | Joint Venture | Biotechnology |
GeneDx Holding ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
26.72 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Healthcare
Industry
of 590
Rank
Percentile
Medical Services
Subindustry
of 97
Rank
Percentile
GeneDx Holding Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Fabric Genomics | Oakland, CA | 2009 |
GeneDx Holding FAQs
-
When was GeneDx Holding founded?
GeneDx Holding was founded in 2000.
-
Where is GeneDx Holding headquartered?
GeneDx Holding is headquartered in Stamford, CT.
-
What is the size of GeneDx Holding?
GeneDx Holding has 1,300 total employees.
-
What industry is GeneDx Holding in?
GeneDx Holding’s primary industry is Other Healthcare Technology Systems.
-
Is GeneDx Holding a private or public company?
GeneDx Holding is a Public company.
-
What is GeneDx Holding’s stock symbol?
The ticker symbol for GeneDx Holding is WGS.
-
What is the current stock price of GeneDx Holding?
As of 20-Nov-2026 the stock price of GeneDx Holding is $45.34.
-
What is the current market cap of GeneDx Holding?
The current market capitalization of GeneDx Holding is $1.36B.
-
What is GeneDx Holding’s current revenue?
The trailing twelve month revenue for GeneDx Holding is $461M.
-
Who are GeneDx Holding’s competitors?
Invitae, Natera, MedGenome Labs, Adaptive Biotechnologies, and Admera Health are some of the 19 competitors of GeneDx Holding.
-
What is GeneDx Holding’s annual earnings per share (EPS)?
GeneDx Holding’s EPS for 12 months was -$3.76.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process